The structural changes roiling the pharmaceutical sector are driving innovation of biotech business models. With shrinking operating margins, patent expirations, a paucity of new product launches, significant reimbursement pressure, and an unpredictable regulatory environment—Big Pharma’s high risk bets on early stage biotechs of the past decade look cavalier through the lens of the current market … Continue reading “The New Normal for Biotech Startups”
Author: James Posada
James Posada Ph.D., MBA is the CEO and a co-founder of Resolve Therapeutics, LLC. Prior to founding Resolve Dr. Posada was the President of Posada & Associates, Inc., a life sciences consulting firm he founded where he advised numerous biotechnology clients and their Boards on strategic transactions and business development. In this capacity he structured and negotiated multiple transactions with pharmaceutical partners on behalf of the firm’s clients. Prior to Posada & Associates, Dr. Posada was the chief business officer of GlycoFi, Inc. where he structured and negotiated company transforming deals with Eli Lilly & Co. and Merck & Co., and played a key role in the sale of the company to Merck for $400 million in 2006. Dr. Posada is a scientist by training having spent several years with Eli Lilly & Company, serving on the management team of the therapeutic proteins division, a 300 person biotech R&D component within Lilly. In this role Dr. Posada had direct line responsibility as well as participated in setting the strategic direction for the group. Dr. Posada started his career in academics as a tenure-track faculty member at the University of Vermont School of Medicine where he ran a basic research lab funded by the National Institutes of Health, and National Science Foundation studying the mechanisms underlying cell signaling. Dr. Posada is the author of over two dozen peer-reviewed publications in top-tier journals such as Science, and the Journal of Biological Chemistry.